XNCR - Xencor: Multiple Data Readouts In Second Half Of 2019 For This 'Picks And Shovels' Play
Shares of Xencor (XNCR) have risen by nearly 400% since its 2013 IPO was priced in the low single digits. On the other hand, over the past 12 months, the stock has risen by just 6% (boosted recently by news that it was joining the S&P SmallCap 600).
When the company came to market, it billed itself as a biopharmaceutical firm focused on engineering monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Xencor boasted a deep roster of internally-discovered programs (some being progressed forward solo, others licensed